Wednesday, July 8, 2026

pharma · Paroxysmal Supraventricular Tachycardia · Atrial Fibrillation · MIST

Milestone Pharmaceuticals

Milestone Pharmaceuticals is a pharma organization headquartered in Montreal, CA. It trades on NYSE under ticker MIST. Primary therapeutic focus areas include Paroxysmal Supraventricular Tachycardia, Atrial Fibrillation,

Montreal, CA HQ
2007 Founded
123 Employees
Public company Type
MIST · NYSE Ticker
Company details
Status
Public
HQ
Montreal, CA
Founded
2007
Employees
123
Programs
8
Drugs
6
Patents
12
Clinical program

Etripamil NS 70 mg

Phase 3 · small molecule · Paroxysmal Supraventricular Tachycardia

Etripamil NS 70 mg for Paroxysmal Supraventricular Tachycardia is a Phase 3 program (small_molecule) at Milestone Pharmaceuticals with 2 ClinicalTrials.gov record(s).

← All Milestone Pharmaceuticals projects Phase 3 small molecule completed

Internal code MSP-2017-1278

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Milestone Pharmaceuticals
Phase
Phase 3
Modality
small_molecule
Indication
Paroxysmal Supraventricular Tachycardia
Status
completed
Trials
2